GL-4512

GL-4512 (10 μM) directly binds recombinant human LILRB4 ECD in a Dianthus/TRIC assay, with a mean ΔF_norm of 27.8% and high assay reproducibility^[1].
GL-4512 (100 pM-1 μM; 15 min) binds recombinant human LILRB4 ECD with high affinity, as measured by MST, with a K_d of 18.1 nM^[1].
GL-4512 (0 to 400 nM; 120 s per injection) directly binds immobilized recombinant human LILRB4 protein, as measured by SPR, with a K_d of 39.2 nM^[1].
GL-4512 (0.0001-10 μM; 60 min) directly engages LILRB4 in CHO cells stably expressing human LILRB4, as measured by CETSA, with an EC₅₀ of 53 nM^[1].
GL-4512 (0.0001-10 μM; 2 h) disrupts the LILRB4-SCG2 interaction in a TR-FRET competition assay, with an IC₅₀ of 37 nM^[1].
GL-4512 (0.0001-10 μM; 1 h) suppresses SCG2-induced inhibitory signaling in THP-1-derived macrophage-like cells expressing LILRB4, with IC₅₀ values of 101 nM for p-SHP1, 141 nM for p-SHP2, and 76.3 nM for p-STAT3^[1].
GL-4512 (0.1-10 μM; 72 h) restores antitumor immune activity in cocultures of colorectal cancer patient-derived PBMCs and HCT116 cells, restoring IFN-γ and IL-2 secretion and reducing tumor cell viability^[1].
GL-4512 (0.1-10 μM; 72 h) restores antitumor immune activity in cocultures of AML patient-derived PBMCs and primary AML blasts, restoring IFN-γ secretion, increasing cytotoxic T-cell activation, and reducing tumor cell viability^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.